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Case Presentation

An 82 year-old male with a past medical history of prostate
cancer, atrial fibrillation, gout, and recently diagnosed myelodysplastic syndrome presented with a chief complaint of left eye
pain. The patient also reported peri-orbital numbness, swelling,
and clear discharge as well as episodic blurry vision of his left
eye. Over the previous two months he had been admitted to the
hospital multiple times complaining of cough and high fevers
and was subsequently treated with several courses of antibiotics
for presumed pneumonia. During the initial admission for
pneumonia he was noted to have a relative pancytopenia. A
bone marrow biopsy was eventually undertaken revealing a
diagnosis of myelodysplastic syndrome (MDS).
Prior to the current presentation, his facial numbness, erythema,
and peri-orbital swelling had persisted over the period of
three weeks. He was seen in an outpatient clinic, diagnosed
with a periorbital cellulitis, and treated with a course of oral
clindamycin, levofloxacin, and erythromycin eye drops. During
his last outpatient follow up he was told to go directly to the
emergency room secondary to the worsening appearance of his
left eye. On current presentation he denied any fevers, chills, or
sweats. He denied traumatic injury to his eye. He also denied
headaches or other neurological complaints but occasionally
experienced blurred vision in his left eye, which usually resolved
spontaneously. He had significant pain around his left eye, which
was worse with eye movements. He denied photophobia and
noted that his symptoms had not improved over the past three
weeks. In addition, he had continuous feelings of numbness
across his left face. He denied sore throat, chest pain, recent
weight loss, myalgias, or arthralgias. His cough had persisted
since his diagnosis of pneumonia and was non-productive in
nature.
His current medications were aspirin, erythromycin eye
drops, levofloxacin, furosemide, digoxin, potassium chloride,
metoprolol, clindamycin, and percocet. He had an allergy
to penicillin, which had caused a rash in the past. He denied
alcohol, tobacco, or substance abuse. A family history was
notable for coronary artery disease and asthma.
On physical exam his vitals were noted to be the following:
temperature 97.6° Fahrenheit, respiratory rate 20 breaths/
minute, heart rate 87 beats/minute, blood pressure 160/90 mm
Hg, and pulse oximetry of 95% on room air. He was noted to
have prominent left periorbital swelling and erythema with a
moderate amount of clear discharge. He had mild periorbital
tenderness and his left sclera appeared injected. The pupils
remained reactive to light and accommodation and his extraoccular movements were intact. The visual acuity in the left
eye was moderately reduced. His cardiac exam revealed only
an irregularly irregular rhythm consistent with known atrial
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fibrillation. His lungs had mildly decreased breath sounds
at the right base but were otherwise clear. His abdomen was
benign. He was neurologically intact with the exception of left
facial numbness. He had mild lower extremity pitting edema
bilaterally.
Laboratory tests revealed a mild pancytopenia: white blood cell
count 3.6 B/L, hemoglobin 8.5 g/dL, and platelet count of 140
B/L. A comprehensive metabolic panel was grossly normal aside
from a mildly elevated BUN and creatinine (21 U/L and 1.6
mg/dL, respectively). An orbital CT scan was quickly obtained
due to the concern for a possible retro-orbital infectious
process. The MRI scan revealed findings consistent with orbital
cellulitis of the left eye with invasive sinusitis. The patient was
emergently taken to the operating room for exploration and
debridement of his maxillary, sphenoid, and ethmoid sinuses.
Subsequent biopsies and cultures revealed a species of rhizopus
fungi as the probable etiology of the patient’s symptoms. He was
diagnosed with invasive mucormycosis involving the left orbit
and sinuses.
The patient underwent multiple surgical procedures on his
sinuses and left orbit. Intraoperatively, he received irrigation
to the affected region with amphotericin B. He also received
systemic therapy with amphotericin until he was noted to have
worsening renal function. He was subsequently started on oral
posaconazole with plans for a prolonged course of treatment.
Following improvement in his symptoms he was discharged
home with appropriate follow up with ophthalmology and
infectious disease.

Discussion

Mucormycosis refers to an infectious condition caused
by a variety of spore-forming organisms belonging to the
zygomycetes class of fungi. These organisms are ubiquitous
in nature, commonly being found in organic substrates such
as soil, plant matter, and animal feces. Humans are routinely
exposed but due to the intact functioning immune systems of
the host, clinical disease is rare. However, in certain susceptible
individuals a much more severe form of disease presentation
can occur.
An important point in the discussion of mucormycosis is the
terminology used to describe zygomycete infections. The class
of zygomycetes is broken down into two subclasses: mucorales
and entomophthorales. Mucormycosis refers to infections
caused by the mucorales subclass of organisms.1 Within the
mucorales subclass are multiple genuses including mucor,
rhizopus, rhizomucor, and absidia.
Mucormycosis was originally described in 1885 and up until the
1950s was considered an exceedingly rare diagnosis. However,
with the sharp increase in certain susceptible populations (e.g.,
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diabetics) over the past 50 years the diagnosis has become
increasingly more common.2

end result of this is additional free iron available to the invading
zygomycete organisms.

Mucormycosis has been described in a variety of different
presentations with multiple organ systems being affected.
Cerebral, pulmonary, renal, gastrointestinal, cutaneous,
disseminated, and ophthalmologic forms have all been described.
Disease can often spread locally to involve surrounding tissues
such as the sinuses in our patient. Infection typically begins with
inhalation of zygomycete spores into the nasopharynx during
an environmental exposure. In the immunocompetent host,
these spores are typically caught by the cilia of the respiratory
tract, expectorated, and are of no further significance. However,
if intact immune mechanisms are lacking in a host, local
infection may begin with the germination of the spores into
fungal elements called hyphae. Localized sites of infection can
spread aggressively and become angioinvasive resulting in
tissue infarction.3 Infection may also spread to distant sites via
hematogenous routes. Other potential sites for initial infection
occur as a result of breakdown in the skin as seen in intravenous
(IV) drug abusers or those with indwelling IV catheters. Most
commonly patients possess some underlying risk factor for
infection; however, case reports with no identifiable risk factor
do exist.4

Perhaps one of the most common examples of a susceptible
host is seen in diabetics. The mechanisms of susceptibility
are two-fold in these patients. Hyperglycemia is a known risk
factor for neutrophil dysfunction and thus presents a risk for
mucormycosis.9 In addition to this, the prominent acidotic states
seen in patients suffering from diabetic ketoacidosis provide an
optimal environment for mucormycosis infection.

Susceptible hosts usually possess a defect in the function of
their mononuclear or polymorphonuclear phagocytes.5 Other
immunosuppressive conditions can also confer risk. The most
prevalent groups of patients who suffer these infections include
those with diabetes, hematologic malignancies, neutropenia,
acidotic states, solid organ or bone marrow transplants, as well
as those who abuse IV drugs and those who are currently on
deferoxamine iron chelation therapy.2,5,6
Iron chelation therapy presents an interesting susceptibility to
mucormycosis organisms. All microorganisms require iron to
survive, and zygomycete organisms are especially sensitive to
this requirement. In the past it has been observed that patients
who carried a diagnosis of iron overload and were treated with
deferoxamine chelation therapy seemed to suffer higher rates of
mucormycosis than other populations.1 In the healthy patient,
free available iron is scarce and difficult for organisms to obtain
for growth as it is bound tightly with normal host proteins.
However, in the patient with excess free iron (e.g., hemochromatosis), zygomycete organisms can exploit elevated levels of
available free iron, and this can result in increased incidence of
clinical disease. Even more susceptible is the patient being treated
with deferoxamine. While this seems paradoxical, it is thought
that zygomycete organisms can specifically use deferoxamine
as a siderophore to sequester iron for growth thus promoting
worsening disease.7 This phenomenon is not seen with other
iron chelators. A similar susceptibility is found in patients with
acidosis. This is believed to be secondary to the inability of
proteins to effectively bind iron in acidotic environments.8 The

Patient presentation is often dictated by the site of infection.
Rhinocerebral mucormycosis is the most common form,
comprising roughly 33% to 50% of all cases.10 Poorly controlled
diabetics represent the major risk factor in this group.1,2 Patients
often present with symptoms of sinusitis (e.g., headache, fever)
combined with facial numbness secondary to involvement
of the fifth cranial nerve. This can rapidly progress to involve
surrounding tissues resulting in ocular involvement (e.g., blurred
vision, proptosis, opthalmoplegia, peri-orbital cellulitis), and in
severe cases can advance into the central nervous system and
surrounding vasculature often resulting in cerebral infarction
secondary to carotid thrombosis or cavernous sinus thrombosis.
A prompt diagnosis requires a high level of suspicion and an
understanding of underlying risk factors for disease. Computed
tomography (CT) and magnetic resonance imaging (MRI)
may show non-specific evidence for soft tissue infection.
Occasionally an eschar may be found on close examination of
skin, nasal airways, or oral mucosa. Immediate consultation with
an otolaryngologist is essential. While antifungal treatment is
needed, survival and limitation of morbidity is usually dictated
by prompt surgical debridement.
Pulmonary mucormycosis typically begins with inhalation of
spores into the lungs; however, less common hematogenous and
lymphatic spread from distant sites to the lungs has also been
described. These patients most often are neutropenic, especially
in the setting of chemotherapy and bone marrow transplant.5
Early complaints are often similar to pneumonia (e.g., fever,
cough, dyspnea, and chest pain). More advanced disease can
present with hemoptysis, often massive in quantity due to the
angioinvasive nature of these infections.5 Diagnosis can be
difficult due to non-specific symptoms and unreliable cultures.
Because of these factors, tissue biopsy is usually required to
confirm the diagnosis. Unfortunately mortality rates can range
from 60% to 95% in pulmonary mucormycosis, with increasing
mortality as the disease process becomes more invasive.2
Cutaneous mucormycosis usually presents with local infection
that has resulted from the breakdown of the normal barrier
defenses in immunocompromised hosts as seen with traumatic
injury, needle injections, and severe burns.1 Prognosis is good,
and surgical therapy can be curative if pursued early; however,
the potential for more severe disease is possible in cases left
untreated.
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Disseminated mucormycosis is perhaps the most severe form
of zygomycete infection. Severe neutropenia, hematologic
malignancies, iron overload, with or without deferoxamine
therapy, and other forms of immunosuppresion carry the
greatest risk for this form of disease.1 Disseminated disease can
spawn from any primary site of infection in the body; however,
pulmonary disease is the most common source.5 The prognosis
for these patients is dismal due to near absence of treatment
options. Surgical therapy is not an option as the spread of
disease is well beyond a focal source.
Other forms of mucormycosis are rare. Gastrointestinal
manifestations involving the stomach, colon and ileum have
been described.5 Similar risk factors are thought to play a role
in these cases. Isolated CNS disease is rare in the absence of
another primary site of infection. It is commonly seen with IV
drug abusers and may present with focal neurologic deficits.2
Other isolated cases of different organ involvement have been
described but the overwhelming majority of cases involve
rhinocerebral, pulmonary, cutaneous, and disseminated forms.
The diagnosis of mucormycosis can be difficult due to the
typically vague symptoms on presentation. Prompt diagnosis
is of the utmost importance in terms of patient survival. An
awareness of at-risk patient populations is needed in order to
prevent a delay in confirming the patient’s diagnosis. Cultures
are unlikely to yield timely results and may be contaminated
due to the ubiquitous nature of the zygomycete organisms.
Ideally, a tissue biopsy is obtained from an affected region of the
patient’s body. Careful preparation of the specimen in the lab is
important as typical grinding of specimens can destroy hyphal
elements and delay diagnosis. Fine mincing of specimens is
the suggested method for preparation and informing the lab of
your suspicions will help in this matter. Laboratory diagnosis
is based solely on microscopic appearance of hyphal elements.
While thin, frequently-septated hyphal elements with regular
branching suggest an alternative type of fungal species such as
aspergillus, the identification of broad (5 to 15 micrometers),
non-septated hyphal elements with irregular branching support
a diagnosis of a zygomycete infection. Radiologic manifestations are unlikely to be diagnostic but can provide supporting
evidence for a diagnosis. In the majority of medical centers
there are no other methods of diagnosis in use such as PCR or
serologic testing.
The treatment for mucormycosis is mostly surgical. Aggressive
and complete resection of all infected tissue is vital to improving
a patient’s chance of survival. Surgical consultation should be
obtained as soon as possible and patients may often require
multiple procedures to obtain adequate margins of resection.
Serial imaging of affected tissues is done to monitor disease
progression and may help guide further surgical procedures.
With the exception of the last few years, the mainstay of medical
therapy consisted solely of amphotericin B for the treatment of
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mucormycosis. More recently some experience with the use of
posaconazole has expanded the options available to clinicians
in the treatment of mucormycosis.11,12 While amphotericin B is
known to carry multiple adverse effects including renal failure
as seen in our patient, posaconazole is an alternative in patients
who cannot tolerate amphotericin B.13 Posaconazole is available
with oral dosing allowing for prolonged outpatient treatment
which may be necessary in certain infections. Other antifungal
medications possess little or no activity against zygomycete
species and should not be used in any therapeutic regimen. The
optimization or elimination of any predisposing risk factors
(e.g., hyperglycemia, acidosis, neutropenia, etc.) should also be
addressed as soon as possible to improve patient outcomes.
There is some interest in using iron chelation therapy as an
adjunctive treatment to surgery and antifungal medications in
the treatment of mucormycosis. Deferiprone (Ferriprox) is a
potent iron chelator that has been used in thousands of patients
outside the United States to successfully treat iron overload.14,15
Deferiprone, unlike deferoxamine, cannot be exploited by fungal
species as a siderophore.16 This would potentially reduce free
iron levels in patient serum, making it more difficult for fungal
species to grow and reproduce. Ibrahim et al, in a rhizopusinfected DKA mouse model, were able to show significant
improvements in survival of mice treated with deferiprone
vs. placebo.16 The applicability in a human host is not proven
at this time, and the use of deferiprone in the treatment of
mucormycosis is available as compassionate use only.
The overall prognosis of patients diagnosed with mucormycosis
is poor. Although outcomes have improved with the use of
amphotericin B, mortaility rates can approach greater than
80% in patients with pulmonary disease. 2 Disseminated
mucormycosis can result in mortality rates approaching 90% to
100%.2 Cutaneous disease, when addressed promptly with local
surgical resection, carries the best prognosis with a greater than
90% survival rate.2 In most cases overall survival will be largely
dictated by the underlying risk factors as well as the timeliness
of surgical intervention.
In summary, mucormycosis represents a highly lethal type
of infection typically affecting specific patient populations.
Immunocompromised patients, diabetics and especially patients
with DKA, oncology patients, patients with iron overload and
those receiving treatment with deferoxamine should be viewed
as having elevated risk for mucormycosis. Prompt consultation
with a surgical team is of utmost importance and should not
be delayed for a confirmed diagnosis. Systemic therapy with
antifungal medication such as amphotericin B or posaconazole
should be instituted quickly but should be viewed only as
adjunctive to successful surgical resection. Overall prognosis
is poor in most forms of disease with the exception of mild
localized cutaneous disease.

Case Reports

References
1.

Kontoyiannis D, Lewis R et al. Invasive Zygomycetes: Update on Pathogenesis,
Clinical Manifestations, and Management. Infect Dis Clin N Am 2006;20:581-607.

2.

Roden M, Zaoutis T, Buchanan W et al. Epidemiology and Outcome of
Zygomycosis: A Review of 929 Reported Cases. Clinical Infectious Disease
2005;41:634-653.

3.

Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis):
emerging clinical importance and new treatments. Curr Opin Infect Dis
2004;17:517.

4.

Sridhara SR, Paragache G, Panda NK, Chakrabarti A. Mucormycosis in immunocompetent individuals: an increasing trend. J Otolaryngol 2005;34(6):402-6.

5.

Spellberg B, Edwards J, Ibrahim A et al. Novel Perspectives on Mucormycosis:
Pathophysiology, Presentation and Management. Clinical Microbiology Reviews
2005;18:556-569.

6.

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin
Microbiol Rev 2000;13:236-301.

7.

Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A,
Van Landuyt HW, Schneider YJ. Mucormycosis during deferoxamine therapy
is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin.
Investing. 1993;91:1979-1986.

8.

Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to
mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes
1982;31:1109-1114.

9.

Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae
in the presence and absence of serum: relationship to hyphal damage mediated
by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect.
Immun. 1982;38:1123-1129.

10. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch. Otolaryngol
1977;103:600-604.
11. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy
for zygomycosis. Antimicrob Agents Chemother 2006;50:126-133.
12. Kok J, Gilroy N, et al. Early use of posaconazole in the successful treatment of
rhino-orbital mucormycosis caused by Rhizopus oryzae. Journal of Infection
2007;55:e33-36.
13. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal
infections: Clinical efficacy and gaps in coverage. Clinical Infectious Diseases
2006;43:1060-1068.
14. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy
for transfusional iron overload. Blood 2003;102:17-24.
15. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of defiriprone
in iron overload in thalasseaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-584.
16. Ibrahim A, Edwards, J et al. Deferiprone iron chelation as a novel therapy
for experimental mucormycosis. Journal of Antimicrobial Chemotherapy
2006;58:1070-1073.

50

